Company Overview
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.20.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -29.06% |
| 6 Months: | -14.02% |
| 3 Months: | -1.30% |
| 1 Month: | +8.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 39.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PLRX Pliant Therapeutics, Inc. PHARMA | 1.14 | -0.76 | $70.59M | 0.00% | -74.87% | -50.29% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 28.94M | 3.60M | 4.81M | 2.17M | 1.79M | 1.61M | 1.25M | 4.99M | 1.48M | 1.33M | 248.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 58.94M | 45.59M | 28.27M | 23.58M | 21.77M |
| Operating Income | - | -15.74M | -13.36M | 11.01M | -16.98M | -16.66M | -22.92M | -22.90M | -27.11M | -28.21M | -29.64M | -31.95M | -42.09M | -47.33M | -47.69M | -52.39M | -60.64M | -62.01M | -58.94M | -45.59M | -28.27M | -23.58M | -21.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.92M | -42.04M | -25.05M | -23.08M | -19.78M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 799.00K | 809.00K | 815.00K | 136.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.17M | -43.30M | -26.30M | -23.58M | -20.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -14.02M | -15.52M | -13.26M | 11.03M | -17.00M | -16.53M | -22.86M | -22.83M | -27.05M | -28.10M | -29.55M | -30.61M | -37.55M | -41.19M | -41.49M | -46.95M | -55.85M | -57.76M | -56.17M | -43.30M | -26.30M | -23.58M | -20.04M |
| Diluted EPS | - | -10.82 | -8.53 | 0.00 | -1.39 | -0.47 | -0.64 | -0.64 | -0.75 | -0.78 | -0.82 | -0.65 | -0.67 | -0.70 | -0.70 | -0.78 | -0.92 | -0.95 | -0.92 | -0.71 | -0.43 | -0.38 | -0.32 |
| R&D Expense | - | 13.10M | 10.78M | 13.92M | 17.54M | 16.88M | 18.53M | 19.22M | 21.05M | 20.88M | 26.34M | 24.61M | 29.27M | 33.00M | 32.34M | 37.15M | 45.62M | 47.75M | 43.44M | 32.20M | 17.94M | - | 13.58M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 57.05M | 41.82M | - | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 136.88M | 185.72M | 228.37M | 156.37M |
| Operating Income | -1.23M | -41.65M | - | -127.20M | -184.15M | -228.37M | -156.37M |
| EBITDA | - | - | - | -120.71M | -158.23M | -205.16M | -145.09M |
| Interest Expense | - | - | - | 791.00K | 1.27M | 3.02M | 2.56M |
| Pretax Income | - | - | - | -123.32M | -161.34M | -210.30M | -149.34M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -631.00K | -41.53M | - | -123.32M | -161.34M | -210.30M | -149.34M |
| Diluted EPS | -4.22 | -1.95 | - | -2.94 | -2.75 | -3.47 | -2.43 |
| R&D Expense | 47.35M | 66.19M | 77.55M | 96.94M | 127.80M | 169.31M | 109.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 119.06M | 295.53M | - | 350.61M | 512.15M | 396.95M | 225.23M |
| Current Assets | - | - | - | - | 340.31M | 505.50M | 362.26M | 196.45M |
| Cash & Equivalents | - | 85.81M | 50.88M | - | 33.69M | 63.23M | 71.19M | 45.45M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 2.00M | 1.98M | 0 | - | - |
| Total Liabilities | - | 9.08M | 12.46M | - | 37.27M | 38.58M | 92.87M | 44.02M |
| Current Liabilities | - | 8.17M | 11.60M | - | 23.91M | 28.52M | 33.22M | 16.36M |
| Long Term Debt | - | - | - | - | 9.93M | 10.05M | 30.21M | - |
| Total Debt | - | - | - | - | 15.81M | 11.37M | 60.19M | 29.11M |
| Total Equity | -71.47M | -76.30M | 283.06M | - | 313.34M | 473.58M | 304.08M | 181.21M |
| Shares Outstanding | - | - | - | - | 48.94M | 59.92M | 60.86M | 61.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.75M | -37.27M | - | -94.63M | -116.36M | -155.50M | -128.34M |
| Investing Cash Flow | -17.93M | -210.87M | - | -150.20M | -127.01M | 140.34M | 134.29M |
| Financing Cash Flow | 45.54M | 213.21M | - | 226.85M | 274.40M | 23.12M | -31.70M |
| Capital Expenditure | -964.00K | -1.53M | - | -1.76M | -921.00K | -3.85M | -374.00K |
| Free Cash Flow | -3.71M | -38.80M | - | -96.39M | -117.28M | -159.35M | -128.71M |
| Net Change in Cash | - | - | - | -17.98M | 31.03M | 7.95M | -25.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -2.2% | -99.6% | - | -1,313.4% | -11,654.7% | - | - |
| Net Margin % | -1.1% | -99.3% | - | -1,273.3% | -10,211.1% | - | - |
| ROE % | 0.8% | -14.7% | - | -39.4% | -34.1% | -69.2% | -82.4% |
| ROCE % | -1.1% | -14.7% | - | -38.9% | -38.1% | -62.8% | -74.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tang Capital Management, LLC | 9.92% | 6.14M | $6.82M |
| 2 | Adar1 Capital Management, LLC | 8.90% | 5.51M | $6.12M |
| 3 | Vanguard Capital Management LLC | 3.94% | 2.44M | $2.71M |
| 4 | Acadian Asset Management. LLC | 3.90% | 2.42M | $2.68M |
| 5 | Two Sigma Investments, LP | 3.65% | 2.26M | $2.51M |
| 6 | Citadel Advisors Llc | 3.46% | 2.14M | $2.38M |
| 7 | Renaissance Technologies, LLC | 3.31% | 2.05M | $2.28M |
| 8 | Monaco Asset Management SAM | 3.13% | 1.94M | $2.15M |
| 9 | Lynx1 Capital Management Lp | 2.90% | 1.80M | $2.00M |
| 10 | BML Capital Management, LLC | 2.50% | 1.55M | $1.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLRX
PLRX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1wbUwyTEdiNFJ2cmhETUtpZlFQWDhtd284cklXaGdaczlyaUJ6MnZ6cUZTeXBudlBEaGNia0NCNnVnZW8wcEZJN1JzeDVwWWlBZXpDWVpmTlpNSGNOX1ItWG02bm1lcnZ4aGUydE9lc3BPVWNOTkxFU1NR?oc=5" target="_blank">PLR…
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOcDlGbER4eXdGNm1wU0EzODI1d01Nd3FFeUxXaFdzNzVVbUotYm5tYUp4clBQaGVva0FJRmNYclZLWjhzeU5iRDk0TmMtMUpVMFN2TEZMWnpqV1E0RFQzbEowTFlGQnhNcW9YaEtwQmwxaFlPSVY1ODhwUmhadTJTTjBfeUhQNGRxVXFVOF…
PLRX - Pliant Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE81c0xIS29FOFF0LVNHdUZrSmlWT2Q3Sm8zQmdFQzFYeGw3cktQRW42clZRZEJoT1lwOS1JaHFKVjFLTzZORnc?oc=5" target="_blank">PLRX - Pliant Therapeutics Inc Stock Price and Quote</a> <fon…
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOX1k2dlFnUlJNYlNFdEkyQlBTLS1EdXZMTUJjZG5WY1VVNXQtMWZlSi1LUkttVHlIYV9RdWNwMU8wUXQzVExWdE5TY0J1ODZPejNHVFFrelM2NTdPajV1QmtBclNjc25tdWVGOFI0ZzVENU5udkhEYUJYTXhCV240dktreEZjR1Q1Y2lKMH…
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTFBvZ0RveHVPYmhTTVhKNU9kd1pfUmV4aGZPY2dpUTdJclRvbGk0TFpoSGFTMWNkSnhhTnlSUTV1d3ZPSTJkVHM2ZDgtb2hkSlpDTlFSRXc0bUtrVmVCdTBvdnM0d2dQT3lUeDNqQlBkUQ?oc=5" target="_blank">Pliant Therapeuti…
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxOSHQwcGI5aFVyenh5NzBsQ0ZiekVIXzl4WVhDZHQzTjJ6MGdaUVdfT0p0WUFCZG42ZmZYcFBneG9YSnB1eWpJWm5iNnMzY2dxU0p1YnlyTnY3UUtWbmFSeTEtOVV5ZkhlNFJ0RHBBNVB6azM1UGZETUZUNHg5d2RIYkZPZmlLQjVaRzRLdk…
PLRX — Frequently Asked Questions
What is the current share price of Pliant Therapeutics, Inc. (PLRX)?
As of 2026-09-19 21:16 PDT, Pliant Therapeutics, Inc. (PLRX) trades at $1.14 on NasdaqGS. Its 52-week range is $1.03 to $1.87.
What is the market capitalisation of PLRX?
Pliant Therapeutics, Inc. (PLRX) has a market capitalisation of $70.59M on NasdaqGS.
What is the P/E ratio of PLRX?
PLRX trades at a trailing price-to-earnings (P/E) ratio of -0.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.47.
What is the return on equity (ROE) of PLRX?
PLRX has a return on equity (ROE) of -50.29%. Its return on capital employed (ROCE) is -74.87%.
Is PLRX a good stock to buy?
This page provides a data-driven analysis of Pliant Therapeutics, Inc. (PLRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.